Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Res ; 69(18): 7473-9, 2009 Sep 15.
Article in English | MEDLINE | ID: mdl-19723659

ABSTRACT

Parathyroid hormone-related protein (PTHrP) is required for mammary gland development and promotes the growth of breast cancer metastases within bone. However, there are conflicting reports of the prognostic significance of its expression in primary breast cancers. To study the role of PTHrP in early breast cancer, the effect of conditional deletion of PTHrP was examined in the context of neu-induced mammary tumorigenesis. Loss of PTHrP resulted in a higher tumor incidence. Transcriptional profiling of the tumors revealed that PTHrP influenced genes relevant to heterotypic cell signaling, including regulators of monocyte recruitment. Immunohistochemical analysis of human breast cancers revealed that PTHrP expression was associated with both HER-2/neu expression and macrophage infiltration in preinvasive ductal carcinoma in situ. The gene expression signature associated with loss of PTHrP expression in vivo correlated with poorer outcome in human breast cancer. Together, these data indicate that loss of PTHrP accelerates mammary tumorigenesis possibly by a non-cell-autonomous tumor suppressor pathway.


Subject(s)
Breast Neoplasms/metabolism , Carcinoma, Intraductal, Noninfiltrating/metabolism , Mammary Neoplasms, Experimental/metabolism , Monocytes/immunology , Parathyroid Hormone-Related Protein/biosynthesis , Animals , Antigens, CD/immunology , Antigens, Differentiation, Myelomonocytic/immunology , Breast Neoplasms/genetics , Breast Neoplasms/immunology , Breast Neoplasms/pathology , Carcinoma, Intraductal, Noninfiltrating/genetics , Carcinoma, Intraductal, Noninfiltrating/immunology , Carcinoma, Intraductal, Noninfiltrating/pathology , Female , Gene Deletion , Gene Expression Profiling , Humans , Lung Neoplasms/genetics , Lung Neoplasms/immunology , Lung Neoplasms/metabolism , Lung Neoplasms/secondary , Male , Mammary Neoplasms, Experimental/genetics , Mammary Neoplasms, Experimental/immunology , Mammary Neoplasms, Experimental/pathology , Mammary Tumor Virus, Mouse/genetics , Mice , Mice, Inbred BALB C , Mice, Transgenic , Monocytes/pathology , Parathyroid Hormone-Related Protein/deficiency , Parathyroid Hormone-Related Protein/genetics , Receptor, ErbB-2/biosynthesis
2.
J Clin Invest ; 119(4): 837-51, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19307728

ABSTRACT

Wnt signaling increases bone mass by stimulating osteoblast lineage commitment and expansion and forms the basis for novel anabolic therapeutic strategies being developed for osteoporosis. These strategies include derepression of Wnt signaling by targeting secreted Wnt pathway antagonists, such as sclerostin. However, such therapies are associated with safety concerns regarding an increased risk of osteosarcoma, the most common primary malignancy of bone. Here, we analyzed 5 human osteosarcoma cell lines in a high-throughput screen for epigenetically silenced tumor suppressor genes and identified Wnt inhibitory factor 1 (WIF1), which encodes an endogenous secreted Wnt pathway antagonist, as a candidate tumor suppressor gene. In vitro, WIF1 suppressed beta-catenin levels in human osteosarcoma cell lines, induced differentiation of human and mouse primary osteoblasts, and suppressed the growth of mouse and human osteosarcoma cell lines. Wif1 was highly expressed in the developing and mature mouse skeleton, and, although it was dispensable for normal development, targeted deletion of mouse Wif1 accelerated development of radiation-induced osteosarcomas in vivo. In primary human osteosarcomas, silencing of WIF1 by promoter hypermethylation was associated with loss of differentiation, increased beta-catenin levels, and increased proliferation. These data lead us to suggest that derepression of Wnt signaling by targeting secreted Wnt antagonists in osteoblasts may increase susceptibility to osteosarcoma.


Subject(s)
Adaptor Proteins, Signal Transducing/genetics , Extracellular Matrix Proteins/deficiency , Gene Silencing , Intercellular Signaling Peptides and Proteins/deficiency , Osteosarcoma/etiology , Osteosarcoma/genetics , Repressor Proteins/genetics , Adaptor Proteins, Signal Transducing/physiology , Animals , Cell Differentiation , Cell Line, Tumor , DNA Methylation , Embryonic Development/genetics , Extracellular Matrix Proteins/genetics , Genes, Tumor Suppressor , Humans , Intercellular Signaling Peptides and Proteins/genetics , Mice , Mice, Knockout , Mice, Transgenic , Osteoblasts/pathology , Osteoblasts/physiology , Promoter Regions, Genetic , Repressor Proteins/physiology , Signal Transduction , Wnt Proteins/physiology
3.
Clin Cancer Res ; 14(16): 5198-208, 2008 Aug 15.
Article in English | MEDLINE | ID: mdl-18698038

ABSTRACT

PURPOSE: The study aim to identify novel molecular subtypes of ovarian cancer by gene expression profiling with linkage to clinical and pathologic features. EXPERIMENTAL DESIGN: Microarray gene expression profiling was done on 285 serous and endometrioid tumors of the ovary, peritoneum, and fallopian tube. K-means clustering was applied to identify robust molecular subtypes. Statistical analysis identified differentially expressed genes, pathways, and gene ontologies. Laser capture microdissection, pathology review, and immunohistochemistry validated the array-based findings. Patient survival within k-means groups was evaluated using Cox proportional hazards models. Class prediction validated k-means groups in an independent dataset. A semisupervised survival analysis of the array data was used to compare against unsupervised clustering results. RESULTS: Optimal clustering of array data identified six molecular subtypes. Two subtypes represented predominantly serous low malignant potential and low-grade endometrioid subtypes, respectively. The remaining four subtypes represented higher grade and advanced stage cancers of serous and endometrioid morphology. A novel subtype of high-grade serous cancers reflected a mesenchymal cell type, characterized by overexpression of N-cadherin and P-cadherin and low expression of differentiation markers, including CA125 and MUC1. A poor prognosis subtype was defined by a reactive stroma gene expression signature, correlating with extensive desmoplasia in such samples. A similar poor prognosis signature could be found using a semisupervised analysis. Each subtype displayed distinct levels and patterns of immune cell infiltration. Class prediction identified similar subtypes in an independent ovarian dataset with similar prognostic trends. CONCLUSION: Gene expression profiling identified molecular subtypes of ovarian cancer of biological and clinical importance.


Subject(s)
Biomarkers, Tumor/analysis , Gene Expression Profiling , Ovarian Neoplasms/genetics , Ovarian Neoplasms/pathology , Adult , Aged , Female , Gene Expression , Humans , Immunohistochemistry , Lasers , Microdissection , Middle Aged , Oligonucleotide Array Sequence Analysis , Ovarian Neoplasms/mortality , Prognosis , Tissue Array Analysis
4.
Dev Genes Evol ; 215(11): 553-63, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16034601

ABSTRACT

This study explored the distribution of parathyroid hormone-related protein (PTHrP) and its mRNA in tissues of the lamprey Geotria australis, a representative of one of the two surviving groups of an early and jawless stage in vertebrate evolution. For this purpose, antibodies to N-terminal and mid-molecule human PTHrP were used to determine the locations of the antigen. Sites of mRNA production were demonstrated by in situ hybridisation with a digoxigenin-labelled riboprobe to exon VI of the human PTHrP gene. The results revealed that antigen and its mRNA were widely distributed among similar sites of tissue localisation to those described for mammalian and avian species. However, some novel sites of localisation, such as in the gill and notochord, were also found. Some differences in PTHrP localisation were noted among individuals at different intervals of the life cycle, indicating that the distributions of PTHrP, and possibly its roles, change with the stage of development in this species. The widespread tissue distribution in G. australis implies diverse physiological roles for this protein. The presence of PTHrP in the lamprey, a representative of a group of vertebrates, which apparently evolved over 540 million years ago, strongly suggests that it is a protein of ancient origin. In addition, the successful use of antibodies and probes based on the human sequence in the lamprey also provides evidence that the PTHrP molecule may have been conserved from lampreys through to humans.


Subject(s)
Evolution, Molecular , Gene Expression Regulation, Developmental/physiology , Lampreys/physiology , Parathyroid Hormone-Related Protein/biosynthesis , Parathyroid Hormone-Related Protein/genetics , Animals , Humans , Immunohistochemistry , Lampreys/anatomy & histology , Lampreys/embryology , Lampreys/genetics , Male , Organ Specificity/genetics , Parathyroid Hormone-Related Protein/chemistry , RNA, Messenger/biosynthesis
5.
Am J Pathol ; 167(1): 117-28, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15972958

ABSTRACT

Giant cell tumor of bone (GCT) is a generally benign, osteolytic neoplasm comprising stromal cells and osteoclast-like giant cells. The osteoclastic cells, which cause bony destruction, are thought to be recruited from normal monocytic pre-osteoclasts by stromal cell expression of the ligand for receptor activator of nuclear factor kappaB (RANKL). This model forms the foundation for clinical trials in GCTs of novel cancer therapeutics targeting RANKL. Using expression profiling, we identified both osteoblast and osteoclast signatures within GCTs, including key regulators of osteoclast differentiation and function such as RANKL, a C-type lectin, osteoprotegerin, and the wnt inhibitor SFRP4. After ex vivo generation of stromal- and osteoclast-enriched cultures, we unexpectedly found that RANKL mRNA and protein were more highly expressed in osteoclasts than in stromal cells, as determined by expression profiling, flow cytometry, immunohistochemistry, and reverse transcriptase-polymerase chain reaction. The expression patterns of molecules implicated in signaling between stromal cells and monocytic osteoclast precursors were analyzed in both primary and fractionated GCTs. Finally, using array-based comparative genomic hybridization, neither GCTs nor the derived stromal cells demonstrated significant genomic gains or losses. These data raise questions regarding the role of RANKL in GCTs that may be relevant to the development of molecularly targeted therapeutics for this disease.


Subject(s)
Bone Neoplasms/genetics , Carrier Proteins/metabolism , Giant Cell Tumor of Bone/genetics , Membrane Glycoproteins/metabolism , Osteoclasts/metabolism , Cell Differentiation/physiology , Cell Lineage , DNA Primers , Flow Cytometry , Gene Expression , Gene Expression Profiling , Histiocytoma, Benign Fibrous/genetics , Humans , Immunohistochemistry , Leiomyosarcoma/genetics , Liposarcoma/genetics , Nucleic Acid Hybridization , Proteins/analysis , RANK Ligand , RNA, Messenger/analysis , Receptor Activator of Nuclear Factor-kappa B , Reverse Transcriptase Polymerase Chain Reaction , Sarcoma, Synovial/genetics
6.
J Cell Biol ; 167(5): 925-34, 2004 Dec 06.
Article in English | MEDLINE | ID: mdl-15583032

ABSTRACT

The molecular basis for the inverse relationship between differentiation and tumorigenesis is unknown. The function of runx2, a master regulator of osteoblast differentiation belonging to the runt family of tumor suppressor genes, is consistently disrupted in osteosarcoma cell lines. Ectopic expression of runx2 induces p27KIP1, thereby inhibiting the activity of S-phase cyclin complexes and leading to the dephosphorylation of the retinoblastoma tumor suppressor protein (pRb) and a G1 cell cycle arrest. Runx2 physically interacts with the hypophosphorylated form of pRb, a known coactivator of runx2, thereby completing a feed-forward loop in which progressive cell cycle exit promotes increased expression of the osteoblast phenotype. Loss of p27KIP1 perturbs transient and terminal cell cycle exit in osteoblasts. Consistent with the incompatibility of malignant transformation and permanent cell cycle exit, loss of p27KIP1 expression correlates with dedifferentiation in high-grade human osteosarcomas. Physiologic coupling of osteoblast differentiation to cell cycle withdrawal is mediated through runx2 and p27KIP1, and these processes are disrupted in osteosarcoma.


Subject(s)
Bone Neoplasms/metabolism , Carrier Proteins/metabolism , Cell Differentiation/genetics , DNA-Binding Proteins/metabolism , Intracellular Signaling Peptides and Proteins/metabolism , Osteoblasts/metabolism , Osteosarcoma/metabolism , Transcription Factors/metabolism , Animals , Bone Neoplasms/genetics , Carrier Proteins/genetics , Cell Cycle Proteins/genetics , Cell Cycle Proteins/metabolism , Cell Line, Tumor , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/metabolism , Core Binding Factor Alpha 1 Subunit , Cyclin-Dependent Kinase Inhibitor p27 , Cyclins/genetics , Cyclins/metabolism , DNA-Binding Proteins/genetics , Feedback, Physiological/genetics , G1 Phase/genetics , Gene Expression Regulation, Neoplastic/genetics , Genes, cdc/physiology , Humans , Intracellular Signaling Peptides and Proteins/genetics , Mice , NIH 3T3 Cells , Osteocalcin/metabolism , Osteosarcoma/genetics , Phenotype , Phosphorylation , Proliferating Cell Nuclear Antigen/metabolism , Retinoblastoma Protein/genetics , Retinoblastoma Protein/metabolism , Transcription Factor AP-2 , Transcription Factors/genetics
7.
Oncogene ; 23(36): 6136-45, 2004 Aug 12.
Article in English | MEDLINE | ID: mdl-15208652

ABSTRACT

One common characteristic of breast cancers arising in carriers of the predisposition gene BRCA1 is a loss of expression of the CDK inhibitor p27(Kip1) (p27), suggesting that p27 interacts epistatically with BRCA1. To investigate this relationship, we examined expression of p27 in mice expressing a dominant negative allele of Brca1 (MMTV-trBr) in the mammary gland. While these mice rarely develop tumors, they showed a 50% increase in p27 protein and a delay in mammary gland development associated with reduced proliferation. In contrast, on a p27 heterozygote background, MMTV-trBrca1 mice showed an increase in S phase cells, and normal mammary development. p27 was the only protein in the cyclin-cyclin-dependent kinase network to show altered expression, suggesting that it may be a central mediator of cell cycle arrest in response to loss of function of BRCA1. Furthermore, in human mammary epithelial MCF7 cells expressing BRCA1-specific RNAi and in the BRCA1-deficient human tumor cell line HCC1937, p27 is elevated at the mRNA level compared to cells expressing wild-type BRCA1. We hypothesize that disruption of BRCA1 induces an increase in p27 that inhibits proliferation. Accordingly, reduction in p27 expression leads to enhancement of cellular proliferation in the absence of BRCA1.


Subject(s)
Cell Cycle Proteins/metabolism , Genes, BRCA1 , Mammary Glands, Human/growth & development , Tumor Suppressor Proteins/metabolism , Animals , Cell Cycle , Cell Cycle Proteins/genetics , Cell Line , Cyclin-Dependent Kinase Inhibitor p27 , Epistasis, Genetic , Epithelial Cells/metabolism , Heterozygote , Humans , Kinetics , Mammary Glands, Human/anatomy & histology , Mammary Glands, Human/metabolism , Mammary Tumor Virus, Mouse/genetics , Mice , Mutation , Tumor Suppressor Proteins/genetics
8.
Int J Radiat Oncol Biol Phys ; 55(3): 713-23, 2003 Mar 01.
Article in English | MEDLINE | ID: mdl-12573759

ABSTRACT

PURPOSE: Signaling pathways initiated by the epidermal growth factor receptor (EGFR) play important roles in the response to ionizing radiation. In this study the consequences of inhibiting the EGFR on the response of A431 cells (human vulvar squamous cell carcinoma cells that overexpress EGFR) to radiation, were investigated in vitro and in vivo, using the selective EGFR-tyrosine kinase inhibitor, ZD1839 ("Iressa"). METHODS AND MATERIALS: The effect of ZD1839 on proliferation, apoptosis, and clonogenic survival after radiation was determined in vitro. For in vivo studies, athymic nude mice with established subcutaneous A431 xenografts (approximately 100 mm(3)) were treated with either a single 10 Gy fraction or 4 daily 2.5 Gy fractions of radiation with or without ZD1839 (75 mg/kg/day intraperitoneally for 10 days) to determine effects on tumor growth delay. RESULTS: Treatment of A431 cells with ZD1839 in vitro reduced proliferation, increased apoptosis, and reduced clonogenic survival after radiation. Strikingly greater than additive effects of ZD1839 in combination with radiation on tumor growth delay were observed in vivo after either a single 10 Gy fraction (enhancement ratio: 1.5) or multiple 4 x 2.5 Gy fractions (enhancement ratio: 4). ZD1839 reduced tumor vascularity, as well as levels of vascular endothelial growth factor (VEGF) protein and mRNA induced by stimulation with epidermal growth factor (EGF), suggesting a possible role of inhibition of angiogenesis in the effect. CONCLUSIONS: Inhibiting EGFR-mediated signal transduction cascades with ZD1839 potentiates the antitumor effect of single and multiple fractions of radiation. These data provide preclinical rationale for clinical trials of EGFR inhibitors including ZD1839 in combination with radiation.


Subject(s)
Antineoplastic Agents/therapeutic use , Apoptosis/radiation effects , Carcinoma, Squamous Cell/radiotherapy , Epidermal Growth Factor/antagonists & inhibitors , Quinazolines/therapeutic use , Radiation-Sensitizing Agents/therapeutic use , Animals , Cell Division/radiation effects , Drug Screening Assays, Antitumor , Endothelial Growth Factors/metabolism , ErbB Receptors/antagonists & inhibitors , ErbB Receptors/metabolism , Female , Gefitinib , Humans , Intercellular Signaling Peptides and Proteins/metabolism , Lymphokines/metabolism , Mice , Mice, Nude , Phosphorylation/radiation effects , Radiotherapy Dosage , Tumor Cells, Cultured/radiation effects , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...